Hematopoietic stem cell transplantation for adult patients with isolated NPM1 mutated acute myeloid leukemia in first remission

Xavier Poire*, Myriam Labopin, Emmanuelle Polge, Didier Blaise, Patrice Chevallier, Johan Maertens, Eric Deconinck, Edouard Forcade, Alessandro Rambaldi, Gabriela M. Baerlocher, Tsila Zuckerman, Liisa Volin, Harry C. Schouten, Norbert Ifrah, Mohamad Mohty, Jordi Esteve, Arnon Nagler

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

10 Citations (Web of Science)

Abstract

Acute myeloid leukemia (AML) in first remission (CR1) with isolated NPM1 mutation (iNPM1m) is considered a good prognosis genotype, although up to one-third relapse. To evaluate the best transplant strategy, we retrospectively compared autologous stem cell transplantation (auto-SCT), related (MSD), and fully matched unrelated (MUD) allogeneic stem cell transplantation (allo-SCT). We identified 256 adult patients including 125 auto-SCT, 72 MSD, and 59 MUD. The 2-year leukemia-free survival (LFS) was 62% in auto-SCT, 69% in MUD, and 81% in MSD (P = .02 for MSD vs others). The 2-year overall survival (OS) was not different among auto-SCT, MUD, and MSD, reaching 83% (P = .88). The 2-year non-relapse mortality (NRM) was 2.5% in auto-SCT and 7.5% in allo-SCT (P = .04). The 2-year cumulative incidence of relapse (RI) was higher after auto-SCT (30%) than after MUD (22%) and MSD (12%, P = .01). In multivariate analysis, MSD versus auto-SCT but not MUD versus auto-SCT was associated with lower RI (P <.01 and P = .13, respectively) and better LFS (P = .01 and P = .31, respectively). Age correlated with higher NRM (P <.01). Allo-SCT using MSD appears as a reasonable transplant option for young patients with iNPM1m AML in CR1. Auto-SCT was followed by worse RI and LFS, but similar OS to both allo-SCT modalities.

Original languageEnglish
Pages (from-to)231-239
Number of pages9
JournalAmerican Journal of Hematology
Volume94
Issue number2
DOIs
Publication statusPublished - Feb 2019

Keywords

  • BONE-MARROW-TRANSPLANTATION
  • ACUTE MYELOCYTIC-LEUKEMIA
  • MINIMAL RESIDUAL DISEASE
  • NO-DONOR ANALYSIS
  • WORKING PARTY
  • INTENSIVE CHEMOTHERAPY
  • EUROPEAN-SOCIETY
  • AML PATIENTS
  • MUTATIONS
  • BLOOD

Cite this